GlassScriptPhysician profile
Molly Emmert
NPI 1881608735
$1,704.45
in general payments reported to CMS, 2019-2025
27 companies · $310 in 2025
The $310 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $509 · 2020: $72.51 · 2021: $66.37 · 2023: $252 · 2024: $495 · 2025: $310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,056.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,056.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $485.58 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Janssen Pharmaceuticals, INC | $178.65 | 2019 | |
| Abbott Laboratories | $159.66 | 2023-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Pfizer INC. | $103.19 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $102.21 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $99.28 | 2023-2025 | |
| Exact Sciences Corporation | $89.54 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $60.40 | 2019-2020 | |
| Lilly USA, LLC | $47.99 | 2024-2025 | Mounjaro, Zepbound, Kisunla |
| Amgen INC. | $47.28 | 2019-2025 | Repatha, Otezla, Repatha |
| Amarin Pharma, INC. | $46.21 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.15 | 2019-2025 | Jardiance |
| Daiichi Sankyo INC. | $31.98 | 2019 | |
| Organogenesis INC. | $24.39 | 2023 | Puraply |
| Medtronic, INC. | $23.26 | 2025 | Minimed 780g |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $21.11 | 2025 | Gemtesa |
| Otsuka America Pharmaceutical, INC. | $18.19 | 2024 | Rexulti |
| Sanofi-Aventis U.S. LLC | $17.60 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.30 | 2025 | Caplyta |
| Glaxosmithkline, LLC. | $13.65 | 2024 | Trelegy Ellipta, Arexvy |
| Novartis Pharmaceuticals Corporation | $13.57 | 2019 | |
| Circassia INC. | $12.73 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.23 | 2019 | |
| Allergan, INC. | $11.90 | 2019 | |
| Roche Diagnostics Corporation | $11.64 | 2019 | |
| Astellas Pharma US INC | $11.45 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Molly Emmert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.